Mounjaro vs Ozempic for Obesity; New Microwave Ablation System; GAHT Erythrocytosis

A real-world, preprint study in medRxiv found that people with overweight or obesity were up to three times more likely to lose significant weight with tirzepatide (Mounjaro) than with semaglutide (Ozempic), though the study used formulations for type 2 diabetes, in which semaglutide comes at a lower dose than its formulation for chronic weight management (Wegovy).

Speaking of which, why did Eli Lilly give tirzepatide the new brand name Zepbound for its obesity indication? (Endpoints News)

These appetite-curbing obesity meds may have people navigating the holidays differently. (NPR)

The FDA cleared a microwave ablation system used to remove soft tissues like thyroid nodules, said Baird Medical.

The average fertility rate was higher in the first half of 2023 in states with abortion bans compared with states that did not have bans, a study found. (CNN)

In patients receiving testosterone for gender-affirming hormone therapy (GAHT), higher testosterone levels were associated with significantly higher hematocrit levels, but absolute levels remained in the normal range and erythrocytosis was rare. (Journal of Clinical Endocrinology & Metabolism)

A meta-analysis found swapping animal-based foods for plant-based ones significantly lowered the risk of type 2 diabetes incidence, cardiovascular disease, and all-cause mortality. (BMC Medicine)

A weight-loss antibody treatment for people deficient in the hormone leptin was both safe and effective in a phase I study. (Science Translational Medicine)

Disease-modifying anti-rheumatic drugs used for rheumatoid arthritis may help prevent the development of autoimmune thyroid disease, too. (Journal of Internal Medicine)

Growth hormone (GH) secretion was inversely tied with high-sensitivity C-reactive protein levels in those with GH deficiency caused by nonfunctioning pituitary masses. (Journal of the Endocrine Society)

Produce prescription programs improved health outcomes for people with diabetes and those on Medicaid. (STAT)

Semaglutide-maker Novo Nordisk will invest $2.3 billion into boosting its diabetes and obesity drug production in France in order to keep up with growing demand. (Reuters)

Please enable JavaScript to view the

comments powered by Disqus.